The iScore predicts clinical response to tissue plasminogen activator in Korean stroke patients.

[1]  A. Demchuk,et al.  The iScore predicts efficacy and risk of bleeding in the National Institute of Neurological disorders and Stroke Tissue Plasminogen Activator Stroke Trial. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[2]  Peter Sandercock,et al.  Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Systematic Review and Meta-Analysis of 55 Studies , 2012, Stroke.

[3]  Ning Zhang,et al.  A Risk Score Based on Get With the Guidelines–Stroke Program Data Works in Patients With Acute Ischemic Stroke in China , 2012, Stroke.

[4]  Eric E. Smith,et al.  Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator , 2012, Stroke.

[5]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[6]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[7]  Gary A. Ford,et al.  Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase: Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score , 2012, Stroke.

[8]  P. Austin,et al.  The iScore Predicts Effectiveness of Thrombolytic Therapy for Acute Ischemic Stroke , 2012, Stroke.

[9]  M. Kaste,et al.  Symptomatic intracranial hemorrhage after stroke thrombolysis: The SEDAN Score , 2012, Annals of neurology.

[10]  M. Kaste,et al.  Predicting outcome of IV thrombolysis–treated ischemic stroke patients , 2012, Neurology.

[11]  P. Austin,et al.  The iScore Predicts Poor Functional Outcomes Early After Hospitalization for an Acute Ischemic Stroke , 2011, Stroke.

[12]  C. Gerloff,et al.  Pretreatment Diffusion-Weighted Imaging Lesion Volume Predicts Favorable Outcome After Intravenous Thrombolysis With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke , 2011, Stroke.

[13]  Gustavo Saposnik,et al.  IScore: A Risk Score to Predict Death Early After Hospitalization for an Acute Ischemic Stroke , 2011, Circulation.

[14]  J. Jeng,et al.  Get With The Guidelines-Stroke Performance Indicators: Surveillance of Stroke Care in the Taiwan Stroke Registry: Get With The Guidelines-Stroke in Taiwan , 2010, Circulation.

[15]  V. Hachinski,et al.  The Canadian Neurological Scale and the NIHSS: Development and Validation of a Simple Conversion Model , 2010, Cerebrovascular Diseases.

[16]  D. Tanné,et al.  A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. , 2008, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[17]  G Schlaug,et al.  The HAT Score , 2008, Neurology.

[18]  Zsolt Garami,et al.  Site of Arterial Occlusion Identified by Transcranial Doppler Predicts the Response to Intravenous Thrombolysis for Stroke , 2007, Stroke.

[19]  Werner Hacke,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.

[20]  David M. Kent,et al.  The Stroke–Thrombolytic Predictive Instrument: A Predictive Instrument for Intravenous Thrombolysis in Acute Ischemic Stroke , 2006, Stroke.

[21]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[22]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .